Several studies have shown that in cancer an increase of mesenchymal characteristics (N-cadherin and vimentin) and loss of epithelial characteristics (E-cadherin) via EMT is proportional with cancer progression, motility, invasiveness, drug resistance and metastasis [72]–[75]. Here, CDH2 is linked to cancer.